Figure 2
From: IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
These charts with mean and standard deviation lines show four-monthly score changes from baseline on the scale for the assessment and rating of ataxia (SARA) during two years of treatment with IGF-1. Data from this extension study suggests that IGF-1 treatment might be effective for reducing the progression of SCAs long-term: Total number of patients (10) (top), SCA3 (6 patients) (middle), and SCA 7 (4 patients) (bottom) subgroups.